Latest News about DSNKY
Recent news which mentions DSNKY
From Benzinga
 From Benzinga
 From Benzinga
 
   FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
   
  
  
  January 28, 2025
  From Benzinga
 From Benzinga
 
   After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
   
  
  
  December 06, 2024
  From Benzinga
 
   Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
   
  
  
  September 23, 2024
  From Benzinga
 
   Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
   
  
  
  September 17, 2024
  From Benzinga
 
   AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
   
  
  
  September 10, 2024
  From Benzinga
 Tickers 
   DSNKY
  
  
  From InvestorPlace
 From Benzinga
 From Benzinga
 From InvestorPlace
 From Benzinga
 
   Why Is AstraZeneca Stock Trading Lower On Tuesday?
   
  
  
  May 28, 2024
  From Benzinga
 Tickers 
   DSNKY
  
  
  From InvestorPlace
 
   Double Good News For AstraZeneca's Breast Cancer Drugs
   
  
  
  April 29, 2024
  From Benzinga
 
   AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
   
  
  
  April 08, 2024
  From Benzinga
 
   What's Going On With Pfizer Stock Today?
   
  
  
  January 25, 2024
  From Benzinga
 From Benzinga
 From Benzinga
 From Motley Fool
 
   Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
   
  
  
  September 22, 2023
  From Benzinga
 
   AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
   
  
  
  September 11, 2023
  From Benzinga
 
   FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
   
  
  
  July 21, 2023
  From Benzinga
 From Benzinga
 
   AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
   
  
  
  July 03, 2023
  From Benzinga
 
   Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
   
  June 27, 2023
  Tickers 
   DSNKY
  
  
  From Benzinga
 
   Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
   
  
  
  March 20, 2023
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
